Background: The T2238C variant of the atrial natriuretic peptide (ANP) gene has emerged as a novel risk factor for the incidence of cardiovascular events. However, the impact of this variant on cardiovascular outcome in patients with atrial fibrillation (AF) is unknown. Methods: We included 557 anticoagulated patients with non-valvular AF randomly selected from the prospective ATHERO-AF cohort. Patients underwent genetic analysis for the T2238C/ANP variant and were grouped as wild type or heterozygous or homozygous for C2238 variant allele. Primary endpoint was a composite of cardiovascular events (CVEs) including cardiovascular death, fatal/non-fatal ischemic stroke and myocardial infarction. Overall, 429 patients carried the TT wild type genotype, 110 patients (19.7%) were heterozygous (T/C) and 18 patients (3.2%) were homozygous (CC). Results: Incidence of CVEs was higher in homozygous patients for C2238 allele at unadjusted analysis (log-rank test, p = 0.042 for additive model, p = 0.043 for recessive model). The multivariable Cox proportional hazards regression analysis confirmed that C2238 ANP allele was associated with CVEs in the additive (p = 0.008) and recessive models (p = 0.005). Conclusions: Carrier status for the C2238/ANP variant allele is associated with an increased risk of CVEs in anticoagulated AF patients.

T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation. a substudy from the ATHERO-AF cohort / Pastori, D.; Carnevale, R.; Stanzione, R.; Nocella, C.; Cotugno, M.; Marchitti, S.; Bianchi, F.; Forte, M.; Valenti, V.; Biondi-Zoccai, G.; Schiavon, S.; Vecchio, D.; Versaci, F.; Frati, G.; Violi, F.; Volpe, M.; Pignatelli, P.; Rubattu, S.; Sciarretta, S.. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - 322:(2021), pp. 245-249. [10.1016/j.ijcard.2020.08.077]

T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation. a substudy from the ATHERO-AF cohort

Pastori D.;Carnevale R.
;
Stanzione R.;Nocella C.;Cotugno M.;Marchitti S.;Valenti V.;Biondi-Zoccai G.;Schiavon S.;Vecchio D.;Frati G.;Violi F.;Volpe M.;Pignatelli P.;Rubattu S.
;
Sciarretta S.
2021

Abstract

Background: The T2238C variant of the atrial natriuretic peptide (ANP) gene has emerged as a novel risk factor for the incidence of cardiovascular events. However, the impact of this variant on cardiovascular outcome in patients with atrial fibrillation (AF) is unknown. Methods: We included 557 anticoagulated patients with non-valvular AF randomly selected from the prospective ATHERO-AF cohort. Patients underwent genetic analysis for the T2238C/ANP variant and were grouped as wild type or heterozygous or homozygous for C2238 variant allele. Primary endpoint was a composite of cardiovascular events (CVEs) including cardiovascular death, fatal/non-fatal ischemic stroke and myocardial infarction. Overall, 429 patients carried the TT wild type genotype, 110 patients (19.7%) were heterozygous (T/C) and 18 patients (3.2%) were homozygous (CC). Results: Incidence of CVEs was higher in homozygous patients for C2238 allele at unadjusted analysis (log-rank test, p = 0.042 for additive model, p = 0.043 for recessive model). The multivariable Cox proportional hazards regression analysis confirmed that C2238 ANP allele was associated with CVEs in the additive (p = 0.008) and recessive models (p = 0.005). Conclusions: Carrier status for the C2238/ANP variant allele is associated with an increased risk of CVEs in anticoagulated AF patients.
2021
ANP; atrial fibrillation; cardiovascular events; genetics; stroke; T2238C
01 Pubblicazione su rivista::01a Articolo in rivista
T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation. a substudy from the ATHERO-AF cohort / Pastori, D.; Carnevale, R.; Stanzione, R.; Nocella, C.; Cotugno, M.; Marchitti, S.; Bianchi, F.; Forte, M.; Valenti, V.; Biondi-Zoccai, G.; Schiavon, S.; Vecchio, D.; Versaci, F.; Frati, G.; Violi, F.; Volpe, M.; Pignatelli, P.; Rubattu, S.; Sciarretta, S.. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - 322:(2021), pp. 245-249. [10.1016/j.ijcard.2020.08.077]
File allegati a questo prodotto
File Dimensione Formato  
Pastori_T2238C_2021.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 639.06 kB
Formato Adobe PDF
639.06 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1470286
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact